Home>Topics>Stocks>Arena Pharmaceuticals

Arena Pharmaceuticals ARNA

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Despite A Bumpy Road Ahead I'm Bullish On CareDx

      Headlines

      Wed, 23 Jul 2014

      lifetime in 2012. It was during that summer that I successfully traded the run-up and/or post approval pops of Arena Pharmaceuticals , Rosetta Genomics, Vivus Inc., Amarin Corp, and Orexigen Therapeutics, Inc. It was that summer of obesity

    2. After Hour Gainers / Losers

      Headlines

      Mon, 21 Jul 2014

      Top gainers, as of 5:15 p.m.: SANM +9.2% . TQNT +7.0% . SNTA +5.4% . APA +4.5% . ARNA +2.1% . Top losers, as of 5:15 p.m.: UCTT -9.4% . RMBS -3.6% . OTCQB:GSAT -2.2% . CTRP -1.4% . TWX -1.3% . Post your comment!

    3. Arena secures Belviq distribution in Israel

      Headlines

      Mon, 21 Jul 2014

      Arena Pharmaceuticals ( ARNA -1.4% ) subsidiary Arena Pharmaceuticals GmbH enters into an exclusive marketing and supply agreement with Teva Pharmaceuticals' local subsidiary Abic Marketing Ltd. to market and distribute Belviq in Israel for

    4. Arena Stock Rises With Expected Jump In Belviq Sales

      Headlines

      Fri, 18 Jul 2014

      This week, we saw an anticipated pop in prescription numbers for the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ). A nice week-over-week climb was expected, considering that the last data we saw fell in the week

    5. Arena Gives Pipeline Exposure - Is The Company Partner Shopping?

      Headlines

      Wed, 16 Jul 2014

      By Spencer Osborne : Arena Pharmaceuticals (NASDAQ: ARNA ) has announced that it was granted U.S. Patent No. 8,778,950 , entitled "Cannabinoid Receptor Modulators" by the United

    6. Arena Stock Holds On Expected Dip In Sales - Bottom May Be In

      Headlines

      Fri, 11 Jul 2014

      By Spencer Osborne : The timing is not great, but the reality is that the prescription numbers this week showed an expected dip because they included the 4th of July Holiday. That is little consolation for longs that saw the equity suffer a 10% dip when the announcement of the sale of shares by CEO

    7. Eisai Metabolic sales force now 600

      Headlines

      Thu, 10 Jul 2014

      Arena Pharmaceuticals ( ARNA ) reports that Eisai has added 200 new contract sales reps in its Metabolic Business Unit. The total number of sales people promoting

    8. Arena Prescription Sales OK - CEO Sales Are Not

      Headlines

      Mon, 7 Jul 2014

      By Spencer Osborne : Sales of Arena Pharmaceuticals ( ARNA ) prescription anti-obesity drug Belviq are in and are okay this week. However, the focus of the week has shifted from script

    9. Arena chief's stock sale invites criticism

      Headlines

      Mon, 7 Jul 2014

      about Belviq's prospects by Arena Pharmaceuticals ( ARNA -8.4% ) CEO Jack Lief has ..... large portion of his holdings of ARNA stock. Mr. Lief felt compelled ..... Q2 2013's debut of $1.3M. ARNA 's stock is down 60% from its

    10. Arena Needs To Hold Eisai Accountable For Re-Launch Of Belviq

      Headlines

      Tue, 1 Jul 2014

      By Spencer Osborne : The very fact that Arena's ( ARNA ) Belviq is being re-launched by marketing partner Eisai ( OTCPK:ESALY ) tells a bigger story than most will openly discuss

    « Prev12345Next »
    Content Partners